WallStSmart

Phunware Inc (PHUN)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 10041% more annual revenue ($258.90M vs $2.55M). PHUN leads profitability with a 0.0% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

PHUN

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 4.0Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PHUNSignificantly Overvalued (-82.5%)

Margin of Safety

-82.5%

Fair Value

$1.03

Current Price

$2.20

$1.17 premium

UndervaluedFair: $1.03Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PHUN2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

PHUN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$45.23M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-11.2%2/10

ROE of -11.2% — below average capital efficiency

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PHUN

The strongest argument for PHUN centers on Price/Book, Revenue Growth. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : PHUN

The primary concerns for PHUN are EPS Growth, Market Cap, Profit Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

PHUN carries more volatility with a beta of 2.66 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 33/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Phunware Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Phunware, Inc. provides an integrated software platform that equips companies with the products, solutions and services to engage, manage and monetize their mobile application portfolios globally. The company is headquartered in Austin, Texas.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?